Fruquintinib as first‐line or second‐line treatment in unresectable or metastatic soft‐tissue sarcoma: A prospective, single‐arm phase II study

• Xiaowei Zhang,
• Ting Zhao,
• Biqiang Zheng,
• Wangjun Yan,
• Yong Chen,
• Yu Xu,
• Chunmeng Wang,
• Junhua Zhang,
• Jian Wang,
• Lin Yu,
• Xin Liu,
• Zhiguo Luo

Affiliations

Xiaowei Zhang

Department of Medical OncologyFudan University Shanghai Cancer CenterShanghaiChina

Ting Zhao

Department of Medical OncologyFudan University Shanghai Cancer CenterShanghaiChina

Biqiang Zheng

Department of OncologyShanghai Medical CollegeFudan UniversityShanghaiChina

Wangjun Yan

Department of OncologyShanghai Medical CollegeFudan UniversityShanghaiChina

Yong Chen

Department of OncologyShanghai Medical CollegeFudan UniversityShanghaiChina

Yu Xu

Department of OncologyShanghai Medical CollegeFudan UniversityShanghaiChina

Chunmeng Wang

Department of OncologyShanghai Medical CollegeFudan UniversityShanghaiChina

Junhua Zhang

Department of OncologyShanghai Medical CollegeFudan UniversityShanghaiChina

Jian Wang

Department of OncologyShanghai Medical CollegeFudan UniversityShanghaiChina

Lin Yu

Department of OncologyShanghai Medical CollegeFudan UniversityShanghaiChina

Xin Liu

Department of Medical OncologyFudan University Shanghai Cancer CenterShanghaiChina

Zhiguo Luo

Department of Medical OncologyFudan University Shanghai Cancer CenterShanghaiChina